VANGUARD THERAPEUTICS, INC. — Department of Health and Human Services SBIR Phase I: DESCRIPTION (provided by applicant): Sickle cell disease (SCD) is a poorly treated
VANGUARD THERAPEUTICS, INC. — SBIR Phase I award from Department of Health and Human Services.
- Amount
- $226,033
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Solicitation
- PA13-234
- NAICS
- —
- Place of performance
- CA
- Period
- —
Description
DESCRIPTION (provided by applicant): Sickle cell disease (SCD) is a poorly treated debilitating condition for which we are developing a promising, new oral prophylactic therapy. A dire need exists for our drug, as millions of patients whohave inherited SCD world-wide, ~100,000 in the US, continue to suffer with episodic pain, disability, and premature death. Hydroxyurea treatment has clear-cut deficiencies, and many drugs under development target treatment rather than prevention of acute events. The cause of most SCD morbidity is abnormal blood flow, notably acute pain crises that result from stoppage of microvascular flow. Defective blood flow results from multiple pathophysiologies, includin several that areindependent of the paradigmatic sequence of deoxygenation -gt sickle hemoglobin polymerization -gt red cell sickling. Based on evidence that endothelial P-selectin is central to ongoing impairment and acute stoppage of flow, we are targeting thi